润都股份(002923.SZ)：公司氢氯噻嗪获得上市批准通知，适用于水肿性疾病等症状

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide, which is expected to enhance the company's product portfolio and market competitiveness, positively impacting future operating performance [1]. Group 1 - The approval of hydrochlorothiazide is applicable for treating edema-related diseases, hypertension, central or renal diabetes insipidus, and nephrolithiasis [1]. - This approval enriches the company's product categories and improves its full industry chain layout [1]. - The development is anticipated to strengthen the company's market competitiveness [1].